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Abstract
Background: Brain metastases (BM) are the most common form of intracranial cancer. The incidence of
BM seems to have increased over the past decade. Recursive partitioning analysis (RPA) of data from three
Radiation Therapy Oncology Group (RTOG) trials (1200 patients) has allowed three prognostic groups
to be identified. More recently a simplified stratification system that uses the evaluation of three main
prognostics factors for radiosurgery in BM was developed.
Methods: To analyze the overall survival rate (OS), prognostic factors affecting outcomes and to estimate
the potential improvement in OS for patients with BM from breast cancer, stratified by RPA class and brain
metastases score (BS-BM). From January 1996 to December 2004, 174 medical records of patients with
diagnosis of BM from breast cancer, who received WBRT were analyzed. The surgery followed by WBRT
was used in 15.5% of patients and 84.5% of others patients were submitted at WBRT alone; 108 patients
(62.1%) received the fractionation schedule of 30 Gy in 10 fractions. Solitary BM was present in 37.9 % of
patients. The prognostic factors evaluated for OS were: age, Karnofsky Performance Status (KPS), number
of lesions, localization of lesions, neurosurgery, chemotherapy, absence extracranial disease, RPA class,
BS-BM and radiation doses and fractionation.
Results: The OS in 1, 2 and 3 years was 33.4 %, 16.7%, and 8.8 %, respectively. The RPA class analysis
showed strong relation with OS (p < 0.0001). The median survival time by RPA class in months was: class
I 11.7, class II 6.2 and class III 3.0. The significant prognostic factors associated with better OS were: higher
KPS (p < 0.0001), neurosurgery (P < 0.0001), single metastases (p = 0.003), BS-BM (p < 0.0001), control
primary tumor (p = 0.002) and absence of extracranial metastases (p = 0.001). In multivariate analysis, the
factors associated positively with OS were: neurosurgery (p < 0.0001), absence of extracranial metastases
(p <0.0001) and RPA class I (p < 0.0001).
Conclusion: Our data suggests that patients with BM from breast cancer classified as RPA class I may be
effectively treated with local resection followed by WBRT, mainly in those patients with single BM, higher
KPS and cranial extra disease controlled. RPA class was shown to be the most reliable indicators of
survival.
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Background
Brain metastases (BM) are the most common form of
intracranial cancer. They exceed the number of primary
brain tumors by at least ten times and occur in about 25%
of all patients with cancer. Most brain metastases origi-
nate from lung (40–50%), breast (15–25%), melanoma
(5–20%), and kidney (5–10%). Brain metastases are
located in the cerebral hemispheres in about 80%, in the
cerebellum in 15%, or in the brainstem in 5% of patients
[1]. The median survival of untreated patients may be as
short as 1–2 months [2-4]. After radiation therapy an
increase in survival is reported in the range from 3 to 6
months [4-6]. The incidence of brain metastases seems to
have increased over the past decade, and may be the par-
adoxical result of the effectiveness of drugs that do not
cross the blood – brain barrier (BBB). As a result of the
increased survival in patients receiving chemotherapy,
brain metastases may become symptomatic [7,8]. Recur-
sive partitioning analysis (RPA) of data from three Radia-
tion Therapy Oncology Group (RTOG) trials (1200
patients) has allowed three prognostic groups to be iden-
tified [9]. RPA class was initially developed to categorize
patients treated with fractionated external beam brain RT
and tested in the radiosurgical treatment of BMs [10-12].
More recently, Lorenzoni et al. [13] proposed a simplified
stratification system that uses the evaluation of three main
prognostics factors for radiosurgery in brain metastases;
this system was called of basic score for brain metastases
(BS-BM), and may be calculated by adding the scores (0 or
1) of three main prognostic factors: KPS, control of the
primary tumor, and existence of extracranial metastases,
ranging from 0 (worst condition) to 3 (best condition)
[13]. In this way, the intention of present study was to
analyze the prognostic factors in our series of patients
with brain metastases from breast cancer treated with
Whole brain radiotherapy (WBRT), with an emphasis on
to test the potential improvement in survival for patients
stratified by the one previously described stratification
system for radiosurgery (BS-BM) and compares it with the
RTOG recursive partitioning analysis.
Methods
The records of 174 patients with brain metastases, who
were treated with WBRT at our institution between Janu-
ary 1996 and December 2004, were analyzed retrospec-
tively. The institutional review boards granted ethical
approval of the study. In the sample of the current study
(n = 174) we use 81 patients with diagnoses of breast can-
cer who had been part of a previous study on WBRT for
Brain metastases from any site [14]. The study was
approved by the institutional review boards. In present
study, at diagnosis of brain metastasis, the following vari-
ables were analyzed for survival: age, location of brain
metastasis, extent of disease, initial Karnofsky score, dose
and fractionation of radiotherapy, surgical resection,
chemotherapy, RPA class and BS-BM, as showed in table-
1. Chemotherapy was administered to the patients with
systemic disease in activity at same time that WBRT. Sup-
portive care (oral corticosteroids) and neurological status
were not evaluated. Brain metastases were detected by
contrast-enhanced cerebral computed tomography (CT)
or magnetic resonance imaging (MRI). Primary tumor
control was defined as remission or stable disease, with-
out any clinical, radiologic, or laboratory findings sugges-
tive of tumor progression at 2 months before WBRT.
According to this criteria twenty patients had local or loco-
regional relapse, the others patients (n = 68) had brain
metastases as first cancer diagnosis. WBRT was performed
in all patients with cobalt 60 gamma rays or with 4 MV
photons of a linear accelerator. The whole brain was irra-
diated by usual opposed lateral fields encompassed the
cranium with a 1 cm margin. Individual shielding blocks
were fabricated for all patients, when necessary. Forty two
patients received WBRT with fields included leptomenin-
ges. The total dose was 30–40 Gy, with a median of 35 Gy,
in daily fractions of 2.0–3.0 Gy. During the study period
two fractionation schemes were used: conventional frac-
tionation with daily fractions of 2 Gray (Gy), five days per
week to a planned total dose of 40 Gy (n = 66) and hypof-
ractionation with daily fractions of 3 Gy, five days per
week to a planned total dose of 30 Gy (n = 108). Surgical
resection was indicated in single brain metastases with
diameter less than or equal to 3 cm, favorable localization
and controlled systemic disease. Biopsy alone and subto-
tal resection were done in 2 and 1 cases, respectively. All
the others patients (n = 24) submitted to surgical resec-
tion were considered gross total resection. The supportive
care (prednisone oral) was introduced at the beginning of
treatment or during radiotherapy. The RPA was used to
classify the patients with brain metastases Class I con-
tained all patients with a Karnofsky performance status
(KPS) ≥ 70, age < 65 years, controlled primary tumor and
no extracerebral metastases, Class III contained patients
with a KPS <70, and Class II contained all other patients
[9]. BS-BM was calculated by adding the scores (0 or 1) of
three main prognostic factors: KPS, control of the primary
tumor, and existence of extracranial metastases [13]. The
BS-BM ranged from 0 (worst condition) to 3 (best condi-
tion).
Statistical Analysis
The endpoint of the study was overall survival. The sur-
vival time was calculated from the starting date of WBRT
to the date of death or last patient contact using the
method of Kaplan Meier. Survival curves were compared
using the log-rank test. The covariates examined in all
cases were: age, sex, location of brain metastasis, extracra-
nial disease, control of primary tumor, initial Karnofsky
score, dose and fractionation radiotherapy schedule, sur-
gical resection, RPA class and BS-BM. All factors with a P-BMC Cancer 2007, 7:53 http://www.biomedcentral.com/1471-2407/7/53
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value ≤ 0.05 at univariate analysis were entered into a
multivariate analysis using the proportional hazards
model (Cox Regression) with confidential interval of
95%.
Results
The overall survival rate in 1, 2 and 3 years was 33.4 %,
16.7%, and 8.8 %, respectively (figure-1). The interval
between the diagnoses of breast cancer and brain metasta-
sis was 32 months (range 0 – 74). The RPA class analysis
showed strong relation with survival (p < 0.0001), table-
2. The median survival time by RPA class in months was:
class I 11.7, class II 6.2 and class III 3.0 as showed in table-
3. According to BS-BM system, the median survival was of
24.6 months for patients with a score of 3, 6.6 months for
patients with a score of 2, 4.7 months for patients with a
score of 1, and 2.8 months for patients with a score of 0 (p
< 0.0001), as demonstrated in table-3. Three patients were
alive in moment of this analysis with a median survival
time of 4.42 years (range, 3.8 – 5.1). All these patients had
Table 1: Characteristic of treatment and patients
AGE MEDIAN RANGE
Patients 57 38 – 82
BRAIN METASTASES SCORE NUMBER %
BM-S O 34 19.5
BM-S 1 54 31
BM-S 2 61 35
BM-S 3 25 14.5
KPS
< 70 89 51.1
>= 70 85 48.8
SURGICAL RESECTION
Yes 27 15.5
No 147 84.5
DOSE(Gy)
FRACTIONATION (fr)
40 Gy/20 fr 66 37.9
30 Gy/10 fr 108 62.1
NUMBER LESIONS
Single 66 37.9
Multiple 108 62.1
CHEMOTHERAPY
Yes 32 18.3
No 142 81.6
RPA CLASS
Class I 39 22.4
Class II 46 26.4
Class III 89 51.2
LOCALIZATION
Supratentorial 140 80.5
Infratentorial 24 13.8
Both 10 5.7
PRIMARY DISEASE CONTROL
Yes 86 49.4
No 88 50.6
EXTRACRANIAL METASTASES
Controlled 80 46
No Controlled 94 54BMC Cancer 2007, 7:53 http://www.biomedcentral.com/1471-2407/7/53
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single brain metastasis, high KPS, cranial extra disease
controlled, submitted to surgical resection before WBRT,
had RPA class 1 and BS-BM 3.
The significant prognostic factors on univariate analysis
associated with better survival were: higher KPS (p <
0.0001), surgical resection (P < 0.0001), single metastases
(p = 0.003), controlled primary tumor (p = 0.002) and
absence of extracranial metastases (p = 0.001), as showed
in table-2 and figures 2, 3, 4, 5, 6. In multivariate analysis,
the factors associated positively with survival were: surgi-
cal resection (p < 0.0001), absence of extracranial metas-
tases (p <0.0001) and RPA class I (p < 0.0001), as
demonstrated in table-4.
Discussion
Whole brain radiotherapy has traditionally been the
standard treatment for patients with brain metastases
since 1950. WBRT has been shown to effectively improve
neurologic symptoms and function for patients with min-
imum co-morbidity. Breast cancer is one of the malignant
tumors that frequently metastasize to the brain [17]. Once
a diagnosis of brain metastasis has been established, prog-
nosis is generally poor [14,18]. In this cohort, the overall
Table 2: Univariate analyses for survival (Log Rank test)
Variable Number Event (n) % P
AGE 132 106 OS 12 months 0.16
< 65 Years 42 36 34.8
>= 65 Years 29.3
KPS <0.0001
< 70 89 75 21.7
>= 70 85 67 45.8
SURGICAL RESECTION <0.0001
Yes 27 20 66.7
No 147 122 26.9
DOSE(Gy)
FRACTIONATION (fr)
0.11
40 Gy/20 fr 66 55 27.6
30 Gy/10 fr 108 87
NUMBER LESIONS 0.003
Single 66 51 43.8
Multiple 108 91
CHEMOTHERAPY 0.29
Yes 32 27 47.8
No 142 122 28.4
RPA CLASS < 0.0001
Class I 39 28 55.6
Class II 46 39 37.7
Class III 89 75 21.7
PRIMARY DISEASE 
CONTROL
0.002
Yes 86 62 46
No 88 80 22.8
EXTRA CRANIAL 
METASTASIS
30.001
Yes 80 50 23.
No 94 92 49
BS-BM < 0.0001
Score 0 34 33 11.8
Score 1 54 52 24.1
Score 2 61 44 42.6
Score 3 25 13 69.2BMC Cancer 2007, 7:53 http://www.biomedcentral.com/1471-2407/7/53
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survival rate in one year was of 33% with a median sur-
vival time 6.4 months. We previously reported a series of
270 patients with brain metastases treated with WBRT
alone with or without surgical resection and, in this series,
the estimated median survival was 4.6 months [14].
The table-5 contains data from the largest studies of
patients with similar diseases who were followed at differ-
ent institutions, and treated with different modalities. The
median survival of 6.4 months reported in our study is
consistent with other reports describing the natural his-
tory and treatment with WBRT alone of breast carcinoma
metastatic to the brain [19,20]. Researchers reporting on
different treatment modalities in similar groups of
patients have noted median survival times in the range of
4 – 16 months after surgery with or without WBRT, SRS or
WBRT alone [19-25], as showed in table-5.
The RTOG has evaluated a number of different radiation
fractionation schemes, but median survival seems inde-
pendent of the dose and schedule [26-29]. In our study,
total dose of WBRT was not a statistically significant pre-
dictor of overall survival. Surgery is an important modal-
ity for patients with a single brain metastasis, particularly
when favorable prognostic factors and systemic disease
control are present [30,31]. Our data showed that patients
undergoing resection of brain lesion followed by WBRT
was associated with significantly better overall survival (p
< 0.0001) than patients submitted to biopsy or WBRT
alone. Patchell et al [15], randomly assigned 48 patients
with single brain metastases (10% with breast primaries)
to surgery followed by WBRT versus WBRT alone. Patients
in the combined arm experienced a longer duration of
functional independence (38 v 8 weeks), and improved
survival (40 v 15 weeks; P < .01). Noordijk et al [30] con-
ducted a randomized trial of 63 patients (19% with breast
primaries) that confirmed and extended these findings.
Importantly, in this study, the benefit of combined-
modality therapy was seen only in patients with stable or
absent extracranial disease. Patients with progressive
extracranial disease at study entry achieved a median sur-
vival of only 5 months, irrespective of the allocated treat-
ment. One additional trial failed to demonstrate a survival
or quality-of-life benefit [31]. Nearly half of the patients
in this trial had extracranial disease, and 10 of 43 patients
randomly assigned to radiotherapy underwent surgical
resection.
The end point of this cohort was to evaluate the different
prognostic factors related with overall survival and to ana-
lyze the importance of recursive partitioning analysis
(RPA) class (RTOG) in patients with brain metastasis. In
our data, the prognostic factors in the univariate analysis
associated with better survival were: Higher KPS, solitary
Overall Survival (Kaplan Meier estimate) Figure 1
Overall Survival (Kaplan Meier estimate).
Table 3: Median survival according to RPA class and BS-BM score.
Characteristics* KPS >= 70, age <65 y, controlled primary no 
extracranial disease
RPA class I Median survival (mo) RPA 11.7
All others RPA class II 6.2
KPS < 70 RPA class III 3.0
BS-BM YES OR NO Median survival (mo) BS-BM
Primary controlled 1 0
KPS > 70 1 0
No metastases extra cranial 1 0
SCORE 3 three factors present 24.6
2 two factors present 6.6
1 one factor present 4.7
0 none factor present 2.8BMC Cancer 2007, 7:53 http://www.biomedcentral.com/1471-2407/7/53
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metastasis, surgical resection, RPA class I, BS-BM -3, con-
trol primary tumor, and absence of extracranial metas-
tases; in the multivariate analysis RPA class I and surgical
resection maintained associated with better survival,
being all these prognostic factors were showed for others
authors in previous studies [9,14,16].
In recent publication, the Radiation Enhancing Allosteric
Compound for Hypoxic Brain Metastases (REACH) study
[32] tested the hypothesis that adding efaproxiral to
WBRT plus supplemental oxygen would improve survival
better than WBRT with supplemental oxygen alone. The
results of this study suggest that efaproxiral, may improve
response rates to WBRT and survival in patients with brain
metastases, mainly metastases from breast cancer. Moreo-
ver, in this phase III study; KPS, number of extracranial
metastatic sites, and sex had the highest statistical signifi-
cance in multivariate analysis. In our study, the others fac-
tors (age, chemotherapy, dose and fractionation
schedule) analyzed were not associated with any effect in
survival. RPA class in this study showed similar results to
RTOG protocols to identify patients with different results
[9], with the median survival time for class I (11.5
months), II (6.2 months) and III (3.0 months) (p =
0.0001), respectively. In this series, the BS-BM was effec-
tive in identifying patients with different outcomes in a
simple and easy manner. A BS-BM of 0 had greater specif-
icity but lower sensitivity BS-BM. However, in our study
BS-BM when compared to RPA class in multivariate anal-
yses did not achieved significant statistical in Cox regres-
sion backward method, this data shows that RPA class is
more powerful and precise than BS-BM in to predict sur-
vival for patients with brain metastases from breast can-
cer. Thus, theses results do not invalidated its use as a
system for predict survival, only it confirms that the RPA
is a more efficient system for this. But, which was the rea-
son for this to occur? Probably this fact occurred because
the BS-BM takes into account only three variables (i.e.,
KPS, primary tumor control, and the presence of extracra-
nial metastases), which have been found in most studies,
as well as in our own evaluation, to be the most important
prognostic factors for survival. Thus it seems that less
important factors had been affected indirectly by the other
main factor as extracranial metastases or surgical resection
Overall Survival by Number of Lesions (Log Rank Test) Figure 3
Overall Survival by Number of Lesions (Log Rank Test).
Table 4: Multivariate analyses of significant factors associated with survival by Cox regression
VARIABLE P HR 95% confidential interval
SURGICAL RESECTION <0.0001 4.34 2.5 7.14
SINGLE METASTASES 0.14 1.08 0.97 1.21
KPS >= 70 0.55 1.31 0.55 3.23
BS-BM 0.58 0.63 0.12 3.29
RPA <0.0001 1.64 1.32 2.04
CONTROL PRIMARY TUMOR 0.66 0.92 0.63 1.34
NO EXTRACRANIAL METASTASES <0.0001 2.38 1.63 3.44
Overall Survival by KPS (Log Rank Test) Figure 2
Overall Survival by KPS (Log Rank Test).BMC Cancer 2007, 7:53 http://www.biomedcentral.com/1471-2407/7/53
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of lesions. Patients with three or more BMs had a greater
proportion of extracranial metastases and smaller than
surgical resection of lesions than those with one or two
BMs (48%vs 22 % and 26% vs 58 %, respectively). In this
way, our data showed that BS-BM system may be used
effectively in patients with brain metastases treated by
WBRT alone or combined with surgery.
Conclusion
In conclusion, both the stratification systems examined
were able to identify quite well those patients who might
or might not benefit from WBRT. RPA class was shown to
be the most reliable indicators of survival. BS-BM has the
advantage of focusing on only three major factors for sur-
vival. Our data suggest that patients with brain metastases
from breast cancer classified as RPA class I may be effec-
tively treated with local resection followed by WBRT,
mainly in those patients with single metastases, higher
KPS and cranial extra disease controlled. We believe that
patients presenting with a RPA Class III or BS-BM of 0 are
clearly not good candidates for surgical resection followed
by WBRT. Patients with RPA Class II or BS-BM of 1 in gen-
eral have a poor outcome, and, in these patients, the deci-
sion concerning treatment remains difficult. Despite the
generally ominous prognosis, some patients still benefit
from surgical ressection. Brain metastases from breast can-
cer pose numerous challenges. Future areas of research
may include characterization of risk factors and in this
way to evaluated new approaches for the treatment of
brain metastases.
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